All tenders
75A50123C00062

DEVELOPING A NEXT-GENERATION VACCINE THAT DRIVES (A) MORE DURABLE AND BROAD ANTI-SPIKE NEUTRALIZING ANTIBODIES (NABS) AGAINST VARIANTS OF CONCERN (VOCS), INCLUDING THOSE NOT INCLUDED IN THE VACCINE, AND (B) T CELLS REACTIVE AGAINST CONSERVED TARGETS

Office of Assistant Secretary for Preparedness and Response · United States

This contract has been awarded. Browse open opportunities
View Source

Time Left to Bid

Awarded

AwardedHealthcare & MedicalFederal

Basic information

Reference number
75A50123C00062
Government level
Federal
Solicitation type
Healthcare & Medical
Title
DEVELOPING A NEXT-GENERATION VACCINE THAT DRIVES (A) MORE DURABLE AND BROAD ANTI-SPIKE NEUTRALIZING ANTIBODIES (NABS) AGAINST VARIANTS OF CONCERN (VOCS), INCLUDING THOSE NOT INCLUDED IN THE VACCINE, AND (B) T CELLS REACTIVE AGAINST CONSERVED TARGETS
Source ID
usa-75A50123C00062

Details

Location
United States

Description

DEVELOPING A NEXT-GENERATION VACCINE THAT DRIVES (A) MORE DURABLE AND BROAD ANTI-SPIKE NEUTRALIZING ANTIBODIES (NABS) AGAINST VARIANTS OF CONCERN (VOCS), INCLUDING THOSE NOT INCLUDED IN THE VACCINE, AND (B) T CELLS REACTIVE AGAINST CONSERVED TARGETS Awarded to: GRITSTONE BIO, INC. Agency: Department of Health and Human Services Sub-agency: Office of Assistant Secretary for Preparedness and Response Award type: DEFINITIVE CONTRACT

Dates

Publication
2023/09/25 12:00:00 AM UTC
Closing date
2025/03/31 12:00:00 AM UTC

Estimated value

$9.9M USD

Classification

Normalized category

Healthcare & Medical

Source: USASpending (Federal)

Last updated 2026-05-25, 2:33:23 p.m.

Data refreshed every 2 hours